Ultragenyx Pharmaceutical (STU:UP0) Total Liabilities : €1,073.5 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Total Liabilities?

Ultragenyx Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 was €1,073.5 Mil.

Ultragenyx Pharmaceutical's quarterly Total Liabilities declined from Sep. 2023 (€1,130.42 Mil) to Dec. 2023 (€1,114.70 Mil) and declined from Dec. 2023 (€1,114.70 Mil) to Mar. 2024 (€1,073.47 Mil).

Ultragenyx Pharmaceutical's annual Total Liabilities increased from Dec. 2021 (€530.86 Mil) to Dec. 2022 (€1,126.15 Mil) but then declined from Dec. 2022 (€1,126.15 Mil) to Dec. 2023 (€1,114.70 Mil).

Ultragenyx Pharmaceutical Total Liabilities Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Total Liabilities Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

433.56

497.46

530.86

1,126.15

1,114.70

Ultragenyx Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,086.17	1,091.24	1,130.42	1,114.70	1,073.47

Ultragenyx Pharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ultragenyx Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	257.161	+	(28.036	+	801.944
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	27.563	+	0)
	=	1,114.7

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1367.259	-	252.555
	=	1,114.7

Ultragenyx Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	225.929	+	(25.741	+	794.148
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	27.653	+	0)
	=	1,073.5

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1202.514	-	129.043
	=	1,073.5

Ultragenyx Pharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical (STU:UP0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RARE:USA RARE:Mexico

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines